Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs placebo for vascular function in rheumatoid arthritis
ACTRN12615000557538Phase 2Terminated
- Sponsor
- A/Prof Stephen Oakley
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA), sponsored by A/Prof Stephen Oakley. Primary endpoint: Peripheral endothelial function measured by EndoPAT at 36 weeks. Started May 2016; status: terminated.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12615000557538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000557538.